Vectura Discontinues VR375 As Phase Three Study Misses Endpoints
LONDON (Alliance News) - Respiratory disease-focused pharmaceutical firm Vectura Group PLC said on Monday its phase three study of VR375 in adult and adolescent patients with severe uncontrolled a
Read more